Treating AD-bearing rats with CeO2NPs resulted in significant depletion (p ˂ 0.05) in serum tau protein and phosphorylated tau accompanied by significant elevation (p ˂ 0.05) in the NG serum level versus the AD-bearing rats, indicating their therapeutic efficacy. This evidence concerns the gene MAPT and Alzheimer disease.